













































Huntington’s disease (HD) is an autosomal dominant 
neurodegenerative disorder with onset usually in middle 
age. Clinical features of HD include uncontrollable 
motor movements, cognitive impairment, and 
psychiatric symptoms [1]. Although the causative gene 
(Huntingtin, HTT) of HD is ubiquitously expressed,  the  
 
 













































polyglutamine (polyQ)-expanded mutant Huntingtin 
protein (Htt) forms nuclear and neutrophil aggregates 
and preferentially affects the striatum and cerebral 
cortex. In addition to altered functions in the central 
nervous system, the expression of mutant Htt was also 
found in peripheral tissues [2-4], and was directly 
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[7], for which an association between dysregulated brain-
type creatine kinase (CKB) and impaired hearing in HD 
mice was demonstrated. Expression levels of CKB in the 
cochlea of two different HD mice models (R6/2 and 
Hdh
(CAG)150) were significantly lower than that of WT 
mice, suggesting that the impairment of CKB in the 
cochlea is likely an authentic defect of HD. Interestingly, 
dietary creatine supplements to HD mice not only 
rescued the expression of cochlear CKB but also restored 
the hearing of HD mice (Figure 1) [7]. It would be of 
great interest in the future to evaluate whether hearing 










































Our findings indicate that the impairment of CKB may 
account for the cochlear energy deficiency which is 
likely a primary cause of the observed hearing loss in 
HD mice [7]. Because the hearing system involves 
high-energy-demanding metabolic processes, CKB is 
likely to play an important role in maintaining normal 
hearing, as well as in pathological hearing impairments 
caused by energy deficiencies in the cochlea. In this 
research perspective, we suggest that hearing loss may 
serve as a biomarker to monitor the progression of HD 
and discuss the potential roles of CKB and the 
phosphocreatine (PCr)-creatine kinase (CK) system in 
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 CKB and HD 
 
It is well known that CK regulates ATP regeneration 
and  energy homeostasis by catalyzing the reversible 
transfer of high-energy phosphate from phosphocreatine 
to ADP [8-11]. Tissues such as the brain, skeletal and 
cardiac muscles, retinas, and spermatozoa express large 
amounts of CK to produce adequate energy stores for 
dynamic energy requirements [12-17]. It is important to 
note that the level of CKB was lower in the cochlea of 
HD mice, where aggregations of mutant Htt (Nlls) were 
also present [7]. The effect of Nlls on the structure and 
function of the cochlea and the interplay between Nlls 
and CKB levels are currently unknown and are worthy 
of further evaluation in the future. Most importantly, we 
found that hearing impairment was closely associated 
with motor deficits, a major symptom of HD patients 
[7]. To date, reliable biomarkers of HD which can be 
used to predict the onset, monitor progression, and/or 
evaluate the efficacy of therapeutic treatment are in high 
demand. The progression of HD is currently evaluated 
using the Unified Huntington's Disease Rating Scale 
(UHDRS) in clinics [18,19]. Nonetheless, the UHDRS 
tends to be subjective, and its sensitivity to disease 
progression is low [20]. Tremendous efforts have been 
devoted to searching for precise and reliable biomarkers 
using various approaches including neuroimaging and 
biochemical analyses [21-31]. Considering that hearing 
tests are generally accessible to HD patients in local 
clinics, we reasoned that hearing loss may be 
considered a new feature of HD patients in clinics as 
well as a potential biomarker for assessing therapeutic 
interventions for HD. 
 
Besides the inferior expression of CKB, alterations in 
mitochondrial functions were extensively explored in 
HD. Well-documented mitochondrial abnormalities 
including dysregulation of a mitochondrial biogenesis 
co-activator (peroxisome proliferator-activated receptor 
gamma coactivator-1α, PGC-1α) [32], abnormal 
calcium homeostasis [33], impaired mitochondrial 
trafficking [34,35], and ATP depletion [36] were 
reported in animals with HD. These findings suggest 
that energy deficits are critical for the pathogenesis of 
HD. Oxidation of CKB, which leads to its reduced 
activity, was also reported in the brain of rodents and 
humans with HD [37,38]. Interestingly, decreased levels 
of CKB in the blood buffy coat fraction were found to 
be associated with presymptomatic and manifesting HD 
patients [39], suggesting a potential application of CKB 
as a biomarker to predict the onset and monitor the 
progression of HD. It is important to note that 
downregulation of CKB was also found in numerous 
neurodegenerative disorders such as Alzheimer's 
disease, Pick's disease, and diffuse Lewy body disease 
[40,41]. Given the importance of CKB in maintaining 
energy homeostasis and appropriate neuronal functions, 
it is worth evaluating whether the level of CKB in white 
blood cells can serve as a reliable biomarker to assess 
the progression of neurodegenerative diseases 
(including HD) in which the level of CKB is reduced in 
the affected brain region(s). 
 
CKB in the cochlea 
 
Mechanoelectrical transduction of cochlear hair cells in 
response to acoustic stimuli involves specialized actin-
cored microvilli called stereocilia, the deflection of 
which leads to potassium influx from the endolymph, 
depolarizes hair cells, and in turn opens voltage-gated 
calcium channels in cell membranes. The influx of 
calcium triggers neurotransmitter release from the basal 
end of the cell into the auditory nerve endings and fires 
the fiber. This sound reception process in the cochlea 
requires energy-intense processes to adequately prime 
the hair bundle movement, for homeostatic calcium 
regulation, and for potassium recycling to repeat the 
cycle [42,43]. Because hair bundles contain no 
mitochondria, an efficient energy supply mechanism to 
maintain a sufficient ATP level for immense energy 
consumption processes in hair bundles [44], such as 
slow and fast adaptation [45], is crucial. The PCr-CK 
system thus plays a critical role in managing high-
energy demands in the cochlea as demonstrated using a 
CKB-knockout mouse model that exhibited preferential 
high-tone hearing loss [44]. 
 
Besides cochlear hair cells, CKB is also localized in the 
inner ear spiral ligament, where several ion transport 
enzymes such as Na, K-ATPase, and carbonic 
anhydrase are expressed to facilitate potassium ion 
cycling back to the endolymph [46-48]. Although the 
role of CKB in the cochlear lateral wall remains 
unclear, it is reasonable to propose that the PCr-CK 
system may also function to shuttle high-energy 
phosphate to replenish ATP at these intracellular sites 
where ATPase hydrolyzes ATP to mediate specialized 
energy demands. It was noted that strial atrophy in aged 
rodent cochleae is associated with an abnormal 
expression profile of CKB [46], suggesting an energy-
supplying role of CKB during disturbed metabolic 
demands in strial atrophy.   
 
ROS-related hearing impairment and the 
antioxidative role of creatine 
 
Age-related sensorineural hearing loss (SNHL) is the 
most common sensory deficit in the elderly population 
[49] and is closely associated with accumulated 
oxidative damage caused by ROS [50-53]. As discussed 
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that tend to produce ROS through mitochondrial 
oxidation. Normally, ROS produced by mitochondria 
during physiological conditions are scavenged by 
endogenous antioxidant mechanisms [54-56]. However, 
when excess ROS following noise overstimulation or 
ototoxic drug insults overwhelm a cell’s natural 
antioxidant defenses, elevated oxidative stress is known 
to contribute to several types of hearing impairment, 
including age-related, noise-induced, and ototoxic drug-
induced SNHL [43,53]. The accumulation of ROS leads 
to genetic and cellular alterations which cause cellular 
dysfunctions such as lipid peroxidation, polysaccharide 
depolymerization, nucleic acid disruption, oxidation of 
sulfhydryl groups, and enzyme inactivation [57], 
consequently leading to permanent cochlear 
degeneration [58-60]. Moreover, a decline in the 
mitochondrial respiratory function and an increase in 
the mitochondrial ROS production may render cells 
more susceptible to apoptosis. Conversely, 
accumulating evidence demonstrated that antioxidants 
and free radical scavengers may serve as effective 
therapeutic agents to block ROS-related activation of 
death mechanisms in multiple systems, including the 
auditory system [43,61-65]. 
 
Creatine is a nitrogenous organic acid which is known 
to increase muscle mass and performance, prevent 
disease-induced muscle atrophy, and facilitate 
supplying energy to cells under a reversible catalyzing 
reaction with CK. Besides its role in energy 
replenishment, creatine also exerts a strong antioxidant 
effect by reducing the intra-mitochondrial production of 
ROS, as well as elevating and preserving the 
mitochondrial membrane potential [66]. In a noise-
induced hearing loss animal model, creatine treatment 
was shown to significantly attenuate the resultant 
auditory threshold shifts [67], suggesting that both the 
maintenance of ATP levels and the scavenging of free 
radicals mediated by creatine are essential for hearing 
protection from such oxidative damage. Since oxidative 
damage caused by ROS has become a common 
pathological cause involved in several types of hearing 
loss, creatine supplements are believed to improve the 
mitochondrial antioxidant defense system and maintain 
optimal energy homeostasis. Further experiments are 
needed to further explore the pleiotropic roles of 




Impaired energy homeostasis recently emerged as an 
important player in a wide variety of neurodegenerative 
diseases. Our earlier findings of the functional roles of 
CKB and the PCr-CK system in hearing loss during HD 
progression strengthen the importance of energy deficits 
in HD pathogenesis. Potential applications of dietary 
creatine supplements and approaches that enhance the 
expression of CKB for degenerative diseases (including 
HD) with energy deficiency and SNHL warrant further 
investigations. 
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